Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329

Watchlist Manager
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Logo
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Watchlist
Price: 29.86 CNY 0.03% Market Closed
Market Cap: 23B CNY
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd stock under the Base Case scenario is 25.82 CNY. Compared to the current market price of 29.86 CNY, Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is Overvalued by 14%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
25.82 CNY
Overvaluation 14%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.4
P/S
P/S
Price to Sales
3.4
vs History
9
vs Industry
37
Median 3Y
3.2
Median 5Y
2.8
Industry
2.4
Forward
2.4
More Details
10.4
P/E
P/E
Price to Earnings
10.4
vs History
95
vs Industry
17
Median 3Y
26
Median 5Y
24.1
Industry
20.5
Forward
16.3
More Details
16.8
P/OCF
P/OCF
Price to OCF
16.8
vs History
96
vs Industry
20
Median 3Y
33
Median 5Y
25.4
Industry
15.6
More Details
18.5
P/FCFE
P/FCFE
Price to FCFE
18.5
vs History
85
vs Industry
24
Median 3Y
25.6
Median 5Y
28.5
Industry
23.1
More Details
2.9
P/B
P/B
Price to Book Value
2.9
vs History
66
vs Industry
19
Median 3Y
3.5
Median 5Y
3.1
Industry
2
More Details
2.9
EV/S
EV/S
Enterprise Value to Sales
2.9
vs History
33
vs Industry
36
Median 3Y
2.9
Median 5Y
2.6
Industry
2.5
Forward
2
More Details
5.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.6
vs History
69
vs Industry
31
Median 3Y
6.6
Median 5Y
6.3
Industry
4.9
More Details
27.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
27.6
vs History
46
vs Industry
11
Median 3Y
29.7
Median 5Y
27.3
Industry
12.3
Forward
10.7
More Details
27.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
27.6
vs History
46
vs Industry
14
Median 3Y
29.7
Median 5Y
27.3
Industry
15.5
Forward
14.5
More Details
14
EV/OCF
EV/OCF
Enterprise Value to OCF
14
vs History
96
vs Industry
21
Median 3Y
30.6
Median 5Y
21.9
Industry
14.1
More Details
15.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
15.5
vs History
96
vs Industry
20
Median 3Y
39.2
Median 5Y
30.6
Industry
17.5
More Details
2.9
EV/IC
EV/IC
Enterprise Value to IC
2.9
vs History
44
vs Industry
27
Median 3Y
3
Median 5Y
2.9
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
23B CNY 3.4 10.4 27.6 27.6
US
Eli Lilly and Co
NYSE:LLY
707B USD 14.4 63.6 34.3 37.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.4B USD 4.2 17.1 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.8 19.5 12.9 14.7
CH
Roche Holding AG
SIX:ROG
204.9B CHF 3.4 24.8 9.3 10.9
CH
Novartis AG
SIX:NOVN
178.1B CHF 4 16.7 9.9 13.2
UK
AstraZeneca PLC
LSE:AZN
158.8B GBP 3.8 27.1 130.3 196.5
US
Merck & Co Inc
NYSE:MRK
194.2B USD 3 11.1 8 9.6
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
116.5B EUR 1.3 9.2 5.1 5.9
P/E Multiple
Earnings Growth PEG
CN
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Average P/E: 22.2
10.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
63.6
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.5
18%
1.1
CH
Roche Holding AG
SIX:ROG
24.8
32%
0.8
CH
Novartis AG
SIX:NOVN
16.7
17%
1
UK
AstraZeneca PLC
LSE:AZN
27.1
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.1
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.2
28%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Average EV/EBIT: 1 699.1
27.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.4
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.7
14%
1
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
13.2
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
196.5
21%
9.4
US
Merck & Co Inc
NYSE:MRK
9.6
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.9
14%
0.4

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.